Compare Adaptive Biotechnologies Corp (ADPT) vs American Water Works Company Inc (AWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs American Water Works Company Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.99 (market cap $3.33B), while American Water Works Company Inc trades at $133.97 (market cap $26.33B). The key difference: American Water Works Company Inc is far larger — about 7.9× Adaptive Biotechnologies Corp's market cap, and American Water Works Company Inc pays a 2.66% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AWK | |
|---|---|---|
Market Cap | $3.33B | $26.33B |
Sector | Health | Utilities |
52-Week High | $22.37 | $147.00 |
52-Week Low | $10.24 | $121.13 |
Enterprise Value | $3.19B | $41.89B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AWK trades at $134.82, down 1.49% today, near the consensus price target of $134.50. The stock shows a bullish technical trend with strong moving averages, while recent earnings have been mixed with two misses in the last three quarters. Revenue grew to $5.14B in 2025, with a net income margin of 21.17%, and the company continues strategic acquisitions and infrastructure investments, as seen in recent news (PRNewsWire, June 30, 2026).
Outlook remains stable with analyst consensus leaning buy (46.66% buy ratings), but risks include high debt levels and regulatory pressures. The stock offers steady growth potential through capital investments, though margin pressures and interest expenses could limit upside. Investors should weigh the defensive utility sector appeal against valuation multiples like a P/E of 23.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
